Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q4 FY2025 Earnings Presentation
21 slides from Aurobindo Pharma's earnings presentation, May 26, 2025
Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
May 26, 2025 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company Cod
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q4FY25
Aurobindo Pharma Limited Earnings Presentation Q4FY25
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q4FY25 Business & Financial Highlights 11 Update on Biosimilars 14 Financial Summary 13 17 Filings Snapshot 3
Slide 5: Q4FY25 Business & Financial Highlights
Q4FY25 Business & Financial Highlights 4
Slide 6: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q4FY25 ₹ 8,382 Cr ₹ 1,792 Cr ₹ 903 Cr Q3FY25 ₹ 7,979 Cr ₹ 1,628 Cr ₹ 846 Cr Q-o-Q growth % 5.1% 10.1% 6.7% 5
Slide 7: Business Highlights – Q4FY25
Business Highlights – Q4FY25 Highest ever quarterly revenues of ₹8,382 Crores with 5.1% growth QoQ Highest ever quarterly EBITDA with a good margin of 21.4%, driven by gross margins and operating efficiencies Net Capex of US$ 90 million* primarily towards capacity enhancements, new business developm
Slide 8: Quarterly Performance – Q4FY25
Quarterly Performance – Q4FY25 Revenue (₹ Crores) US Revenue excluding Puerto Rico (US$ Mn) 8,382 470 7,979 7,796 451 7,580 7,567 435 432 7,352 426 421 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 EBITDA (₹ Crores) Net Debt to Equity 0.04 1,792 0.02 1,687 1,601
Slide 9: Consolidated Business Performance
Consolidated Business Performance Y-o-Y Q-o-Q Y-o-Y ₹ Crores Q4FY25 Q4FY24 Q3FY25 FY25 FY24 (%) (%) (%) USA** 4,072 3,588 13.5% 3,671 10.9% 14,816 13,867 6.8% Europe 2,147 1,832 17.2% 2,121 1.2% 8,356 7,166 16.6% Growth Markets* 786 852 -7.8% 873 -10.0% 3,180 2,517 26.3% ARV 308 238 29.4% 307 0.4% 1
Slide 10: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 480 470 460 • US revenue in Q4FY25 increased by 9% YoY and 435 440 432 increased by 8% QoQ to USD 470 Mn, 420 accounting for 48.6% of consolidated revenue 400 • Filed 9 ANDAs with USFDA in Q4FY25 380
Slide 11: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Crores) 236 236 1,069 103 104 1,019 1,006 203 91 36 36 29 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Growth Markets declined by 12% Europe business posted YoY with modera
Slide 12: Update on Biosimilars
Update on Biosimilars 11
Slide 13: Sustaining the momentum in biosimilars
Sustaining the momentum in biosimilars European Commission (EC) approvals for Dyrupeg, Zefylti. CHMP positive opinion for Dazublys. EC approval expected in July. MHRA approval for Zefylti. Second biosimilar approval after Bevqolva. First supplies of four biosimilars to EU markets by Q3/Q4 FY26. Succ
Slide 14: Continuing progress through an expanding pipeline in 2025-26
Continuing progress through an expanding pipeline in 2025-26 BP11, our biosimilar to Xolair, to complete Phase 3 study in Q3. Target to file in Q4 BP16, our biosimilar to Prolia, will be filed in Q3 BP01, our biosimilar to Avastin, to complete Phase 3 study in Q4 Eight future biosimilar candidates w
Slide 15: Financial Summary
Financial Summary 14
Slide 16: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement ₹ Crores Q4FY25 Q4FY24 YoY (%) Q3FY25 QoQ (%) FY25 FY24 YoY (%) Revenue from Operations 8,382 7,580 10.6% 7,979 5.1% 31,724 29,002 9.4% Gross Profit 4,954 4,519 9.6% 4,663 6.2% 18,697 16,399 14.0% Gross Margin 59.1% 59.6% -51 bps 58.4% 66 bps 58.9% 56.5%
Slide 17: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-21 Mar-22 Mar-23 Mar-24 Mar-25 Closing Rate (INR/USD) 73.110 75.793 82.170 83.405 85.475 592 758 833 966 963 930 Fx Loan restated in INR 4,929 2,223 4,638 3,994 5,883 Rupee Loan 44 150 224 2,324 2,065 232 228 242 196 Gross Debt 4,972 2,373 4,8
Slide 18: Filing Snapshot
Filing Snapshot 17
Slide 19: US ANDA Filings Snapshot as on 31st March 2025
US ANDA Filings Snapshot as on 31st March 2025 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 156 28.4 Aurobindo (Excl. Specialty & 690 800 600 519 Specialty & Injectables 300 700 ARV 29 1.6 600 500 250 500 200 171 Injectables) 400 400 150 49.7 300 300 142 CVS 123 200 200 114 100 5
Slide 20: Global Regulatory Filing Details
Global Regulatory Filing Details As at As at As at As at As at As at As at As at As at Category Geography Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 US* 429 478 541 586 639 727 774 830 861 Europe** 2,521 2,848 3,003 3,214 3,374 3,580 3,751 3,642 3,933 Formulations SA** 401 415 43
Slide 21: Thank You
Thank You Digitally signed by BADDIGAM ADI REDDY Date: 2025.05.26 19:47:48 +05'30' For more information, contact: ir@aurobindo.com; cc@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1551 | 6672 5005 20